Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.

Autor: Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Alayli FA; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Okrah K; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Drakaki A; University of California, Los Angeles , Los Angeles, CA, USA., Khalil DN; Memorial Sloan Kettering Cancer Center , New York, NY, USA., Kummar S; Stanford University , Stanford, CA, USA., Khan SA; Stanford University , Stanford, CA, USA., Hodi FS; Dana-Farber Cancer Institute , Boston, MA, USA.; Parker Institute for Cancer Immunotherapy, Dana-Farber Cancer Institute , Boston, MA, USA., Oh DY; University of California, San Francisco , San Francisco, CA, USA., Cabanski CR; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Gautam S; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Meier SL; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA.; Stanford University , Stanford, CA, USA., Amouzgar M; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Pfeiffer SM; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Kageyama R; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Yang E; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Spasic M; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Tetzlaff MT; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Foo WC; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hollmann TJ; Memorial Sloan Kettering Cancer Center , New York, NY, USA.; Bristol Myers Squibb , New York, NY, USA., Li Y; Memorial Sloan Kettering Cancer Center , New York, NY, USA., Adamow M; Memorial Sloan Kettering Cancer Center , New York, NY, USA., Wong P; Memorial Sloan Kettering Cancer Center , New York, NY, USA., Moore JS; University of Pennsylvania , Philadelphia, PA, USA., Velichko S; Natera Inc. , Austin, TX, USA., Chen RO; Personalis Inc. , Fremont, CA, USA., Kumar D; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Bucktrout S; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Ibrahim R; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Dugan U; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Salvador L; Bristol Myers Squibb , New York, NY, USA., Hubbard-Lucey VM; Cancer Research Institute , New York, NY, USA., O'Donnell-Tormey J; Cancer Research Institute , New York, NY, USA., Santulli-Marotto S; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Butterfield LH; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Da Silva DM; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Fairchild J; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., LaVallee TM; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Padrón LJ; Parker Institute for Cancer Immunotherapy , San Francisco, CA, USA., Sharma P; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; James P. Allison Institute, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.; Immunotherapy Platform, James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Publikováno v: The Journal of experimental medicine [J Exp Med] 2024 Oct 07; Vol. 221 (10). Date of Electronic Publication: 2024 Aug 27.

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.

Autor: O'Hara MH; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., O'Reilly EM; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Varadhachary G; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA., Wolff RA; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA., Wainberg ZA; Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA., Ko AH; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Fisher G; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA., Rahma O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lyman JP; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Cabanski CR; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Mick R; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Gherardini PF; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Kitch LJ; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Xu J; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Samuel T; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Karakunnel J; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Fairchild J; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Bucktrout S; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., LaVallee TM; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Selinsky C; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Till JE; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Carpenter EL; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Alanio C; Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Byrne KT; Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Chen RO; Personalis, Menlo Park, CA, USA., Trifan OC; Apexigen, San Carlos, CA, USA., Dugan U; Bristol Myers Squibb, New York, NY, USA., Horak C; Bristol Myers Squibb, New York, NY, USA., Hubbard-Lucey VM; Cancer Research Institute, New York, NY, USA., Wherry EJ; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Ibrahim R; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Vonderheide RH; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: rhv@upenn.edu.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2021 Jan; Vol. 22 (1), pp. 118-131.

Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction.

Autor: Wells DK; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. Electronic address: dwells@parkerici.org., van Buuren MM; Division of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands; T Cell Immunology, Biopharmaceutical New Technologies (BioNTech) Corporation, BioNTech US, Cambridge, MA, USA., Dang KK; Computational Oncology, Sage Bionetworks, Seattle, WA, USA., Hubbard-Lucey VM; Anna-Maria Kellen Clinical Accelerator, Cancer Research Institute, New York, NY, USA., Sheehan KCF; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, St. Louis, MO, USA; The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO, USA., Campbell KM; Division of Hematology and Oncology, Department of Medicine, Johnson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA., Lamb A; Computational Oncology, Sage Bionetworks, Seattle, WA, USA., Ward JP; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Sidney J; Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA., Blazquez AB; Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Rech AJ; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Zaretsky JM; Division of Hematology and Oncology, Department of Medicine, Johnson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA., Comin-Anduix B; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Surgery, David Geffen School of Medicine, Johnson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA., Ng AHC; Institute for Systems Biology, Seattle, WA, USA., Chour W; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA., Yu TV; Computational Oncology, Sage Bionetworks, Seattle, WA, USA., Rizvi H; Druckenmiller Center for Lung Cancer Research, MSKCC, New York, NY, USA., Chen JM; Division of Hematology and Oncology, Department of Medicine, Johnson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA., Manning P; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Steiner GM; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Doan XC; Computational Oncology, Sage Bionetworks, Seattle, WA, USA., Merghoub T; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Medicine, MSKCC, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Guinney J; Computational Oncology, Sage Bionetworks, Seattle, WA, USA; Biomedical Informatics and Medical Education, University of Washington, Seattle, WA, USA., Kolom A; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Anna-Maria Kellen Clinical Accelerator, Cancer Research Institute, New York, NY, USA., Selinsky C; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Ribas A; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Division of Hematology and Oncology, Department of Medicine, Johnson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA., Hellmann MD; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Druckenmiller Center for Lung Cancer Research, MSKCC, New York, NY, USA; Department of Medicine, MSKCC, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Hacohen N; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Sette A; Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, University of California, San Diego, La Jolla, CA, USA., Heath JR; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Institute for Systems Biology, Seattle, WA, USA., Bhardwaj N; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Ramsdell F; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Schreiber RD; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, St. Louis, MO, USA; The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO, USA., Schumacher TN; Division of Molecular Oncology and Immunology, Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands., Kvistborg P; Division of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands., Defranoux NA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. Electronic address: ndefranoux@parkerici.org.

Publikováno v: Cell [Cell] 2020 Oct 29; Vol. 183 (3), pp. 818-834.e13. Date of Electronic Publication: 2020 Oct 09.

Impact of COVID-19 on oncology clinical trials.

Autor: Upadhaya S, Yu JX, Oliva C, Hooton M, Hodge J, Hubbard-Lucey VM

Publikováno v: Nature reviews. Drug discovery [Nat Rev Drug Discov] 2020 Jun; Vol. 19 (6), pp. 376-377.

Trends in clinical development for PD-1/PD-L1 inhibitors.

Autor: Xin Yu J, Hodge JP, Oliva C, Neftelinov ST, Hubbard-Lucey VM, Tang J

Publikováno v: Nature reviews. Drug discovery [Nat Rev Drug Discov] 2020 Mar; Vol. 19 (3), pp. 163-164.